BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 7481860)

  • 21. Oral estramustine and oral etoposide for hormone-refractory prostate cancer.
    Dimopoulos MA; Panopoulos C; Bamia C; Deliveliotis C; Alivizatos G; Pantazopoulos D; Constantinidis C; Kostakopoulos A; Kastriotis I; Zervas A; Aravantinos G; Dimopoulos C
    Urology; 1997 Nov; 50(5):754-8. PubMed ID: 9372887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The activity of paclitaxel in gastrointestinal tumors.
    Ajani JA; Ilson DH; Kelsen DP
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):46-50; discussion 51-3. PubMed ID: 7481861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination.
    Athanasiadis A; Tsavdaridis D; Rigatos SK; Athanasiadis I; Pergantas N; Stathopoulos GP
    Anticancer Res; 2003; 23(3C):3085-8. PubMed ID: 12926166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
    Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
    Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.
    Lin CC; Hsu CH; Hour TC; Cheng AL; Huang CY; Huang KH; Chen J; Pu YS
    Urol Oncol; 2007; 25(3):207-13. PubMed ID: 17483017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.
    Haas N; Roth B; Garay C; Yeslow G; Entmacher M; Weinstein A; Rogatko A; Babb J; Minnitti C; Flinker D; Gillon T; Hudes G
    Urology; 2001 Jul; 58(1):59-64. PubMed ID: 11445480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
    Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
    J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
    von Pawel J; Wagner H; Niederle N; Heider A; Koschel G; Hecker D; Hanske M
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):47-50. PubMed ID: 9007121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study.
    Klaassen U; Wilke H; Müller C; Borquez D; Harstrick A; Seeber S
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-58-S17-60. PubMed ID: 9374095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estramustine-based chemotherapy.
    Hudes G
    Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.